Thetis Pharmaceuticals Commences Phase 1a Clinical Trial with TP-317, an Oral Resolvin E1 Drug Targeting the LTB4-BLT1 Pathway

First subject dosed in the first-in-human Phase 1 clinical study of TP-317, a novel BLT1 agonist that promotes tissue repair and restores immune homeostasis

ESSEX, Conn — April 4, 2024 — Thetis Pharmaceuticals LLC (“Thetis”) announced today the commencement of a first-in-human Phase 1 clinical study of TP-317 in Australia. The trial is a randomized, single-blind, placebo-controlled, single-ascending dose, clinical study is designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of oral TP-317 in healthy subjects. TP-317 is a first-in-class, oral Resolvin E1 drug candidate that selectively engages BLT1 to promote tissue repair, control inflammation, and restore immune homeostasis.

“This marks an important milestone in the development of TP-317,” said Gary Mathias, co-founder and CEO of Thetis. “TP-317 has the potential to be a best-in-class treatment for inflammatory bowel disease (IBD) based on its unique mechanism of action as an agonist of the BLT1 receptor and potential safety advantages over existing therapies that suppress the immune system.”

Resolvin E1 is a naturally occurring signaling molecule that binds to BLT1, an important G protein-coupled receptor (GPCR) involved in regulating immune responses and acute and chronic inflammation.

“When RvE1 engages BLT1, it clears cellular debris and microbes from inflamed tissue to promote immune homeostasis”, said John Parkinson, chief scientific officer of Thetis. “Other evidence suggests that RvE1 acting through BLT1 promotes intestinal barrier integrity, an important therapeutic goal in the treatment of ulcerative colitis and Crohn’s disease. We believe this mechanism of action can deliver therapeutic benefit in chronic diseases like IBD.”

About Thetis Pharmaceuticals
Thetis is a clinical-stage pharmaceutical company focused on developing innovative treatments for chronic inflammatory diseases and cancer. Thetis’ lead candidate, TP-317, is a first-in-class, oral Resolvin E1 (RvE1) drug that engages the LTB4-BLT1 pathway to harness the body’s natural ability to resolve disease and restore immune homeostasis. Thetis is supported by private investors, the National Institutes of Health, and prominent philanthropies, including the Helmsley Charitable Trust, Crohn's & Colitis Foundation, and Kenneth Rainin Foundation.

Contact
Tracy Lessor
TLOW Communications, LLC
617-519-9827
tracy@tlowcommunications.com